VIDEO: Evolution of hyper-CVAD in ALL
Click Here to Manage Email Alerts
In this video, Lori Muffly, MD, MS, discussed a presentation from the Society of Hematologic Oncology Annual Meeting about the how the use of hyper-CVAD for acute lymphoblastic leukemia has evolved over time.
The presentation, which was given by Elias Jabbour, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson, reviewed the current use of hyper-CVAD as well as how the methodology of administering hyper-CVAD has changed to incorporate blinatumomab (Blincyto, Amgen), inotuzumab ozogamicin (Besponsa, Pfizer) and rituximab (Rituxan; Genentech, Biogen), according to Muffly, who is an associate professor of medicine in the division of blood and marrow transplantation and cellular therapy at Stanford University. Additionally, Jabbour highlighted the emerging importance of measurable residual disease when selecting optimal treatment.
“For the practicing clinician, that talk was quite useful in really understanding how hyper-CVAD has evolved and what the publications would be to support the use of some of these evolved hyper-CVAD variations in your practice,” Muffly said.
Collapse
Jabbour E. Hyper CVAD in 2021: Lessons learned and new approaches. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 8-11, 2021 (virtual meeting).
Click Here to Manage Email Alerts